From prophylaxis to precision immunotherapy via engineering vaccine platforms
Vaccines are evolving from antigen-delivery products into modular technologies designed to elicit specific immune functions. Although prophylactic vaccination aims to establish protective memory before exposure, therapeutic vaccination must redirect immunity in the presence of persistent antigen, immune suppression or pathological tissue remodeling. In this Review, we examine how antigen architecture, innate sensing, antigen-presenting-cell targeting, platform design and administration route jointly determine vaccine-induced immune programmes. We compare the distinct requirements of prevention and treatment, focusing on cancer, chronic viral infection and fibrosis, and assess the opportunities and limitations of RNA vaccines, viral vectors, virus-like particles, adjuvants and combination strategies. We then consider how systems vaccinology and artificial intelligence can inform immunogen design and response prediction, while distinguishing computational promise from experimentally validated benefit. We argue that clinical progress depends on matching each vaccine formulation to a defined biological barrier and demonstrating tissue-level activity, safety, durability and practical deployability. This framework connects vaccine engineering to measurable protective or therapeutic outcomes without assuming that any single platform is universally optimal. By integrating immunological principles with advances in vaccine engineering, this Review provides a conceptual basis for selecting and combining technologies according to disease-specific requirements. Ultimately, this perspective may help guide the development of more precise, adaptable and clinically relevant vaccination strategies, bridging the gap between platform innovation and improved outcomes in prevention and therapy.
Authors
- Otávio Cabral-Marques (ORCID: https://orcid.org/0000-0002-3183-6236)
- Ricardo Durães‐Carvalho (ORCID: https://orcid.org/0000-0001-5734-7601)
- Fernando Giugni (ORCID: https://orcid.org/0000-0001-9268-286X)
- Gustavo Cabral‐Miranda (ORCID: https://orcid.org/0000-0001-8351-4880)
- Bárbara Hamaguchi (ORCID: https://orcid.org/0000-0002-2744-7000)
- Jaqueline Wang da Silva (ORCID: https://orcid.org/0000-0002-8049-149X)
- Jose E. Krieger
- Niels O S Câmara
- Ester C. Sabino
Publication Details
- Journal
- Molecular Biomedicine
- Published
- 2026-11-22
- DOI
- https://doi.org/10.1186/s43556-026-00674-3
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00